Market Overview

Liberty Health Sciences Inc. and Resolve Digital Health Inc. Strike Exclusive Partnership to Provide Floridians with Innovative Cannabis Metered-Dosing Inhalation Solutions

Share:

Liberty Health Sciences Inc. (CSE:LHS) (OTC:LHSIF) ("Liberty" or the
"Company") today announced an exclusive partnership with Resolve Digital
Health Inc. ("Resolve"), a cutting edge developer of medical cannabis
delivery systems and devices. The partnership will see Resolve's
industry-leading smart inhalation products exclusively distributed
through Liberty within the state of Florida, subject to approval of the
same by the Florida Department of Health, Office of Medical Marijuana
Use as is required under Florida law.

Liberty is committed to delivering high-quality, clean and safe
pharmaceutical grade cannabis to patients in need and this partnership
represents yet another important step in enhancing the patient
experience. Resolve's smart technology is based on proprietary
Artificial Intelligence algorithms that track patient usage data through
a mobile application to facilitate sharing with doctors, pharmacists and
other caregivers, and allows patients and health care professionals to
monitor the efficacy of treatment in order to continuously improve their
medical cannabis experience.

"Our partnership with Resolve further supports our commitment to being
industry leaders in the medical cannabis space by offering our patients
innovative and safe methods to inhale cannabis. The Aphria brand is
dedicated to patient well-being which makes the Resolve inhaler a
perfect addition to our product portfolio," said George Scorsis, CEO and
Director of Liberty. "We're very pleased to be partnering with Resolve
to bring their state-of-art technology, and a heightened understanding
of patients' needs to the Florida market."

Resolve is committed to establishing the highest standard of care in the
medical cannabis industry. Breeze Smart Inhalers, their metered-dose
based vaporizer, works in conjunction with the Breeze App to provide a
patent-pending adaptive dosing function. This allows patients to vary
their dose based on their current levels of pain and through machine
learning analysis of their activity patterns, time of day, local weather
conditions, sleep history and other collected and reported data.

"Like Liberty, Resolve's top priority is patient care, and we're excited
to be able to provide a truly unique medical service to patients in
Florida thanks to this partnership," said Rob Adelson, CEO of Resolve.
"Liberty's market expertise makes them the perfect partner to help
provide patients with a sophisticated medical cannabis experience."

For more information on Liberty, please visit www.libertyhealthsciences.com

About Liberty Health Sciences Inc.

Liberty Health Sciences Inc. ("Liberty") is an investor and operator in
the medical cannabis market, capitalizing on new and existing
opportunities in U.S. states where medical cannabis is legal.
Liberty's stringent investment criteria for expansion maximizes returns
to shareholders, while focusing on significant near and
mid-term opportunities. Liberty has an extensive background in highly
regulated industries, with expertise in becoming a low-cost producer.
Liberty leverages commercial greenhouse knowledge to deliver
high-quality, clean and safe pharmaceutical grade cannabis to patients.

About Resolve Digital Health

Resolve Digital Health is positioned to be the leading provider of a
metered dosing ecosystem for medical cannabis devices. The company's
proprietary technology, apps and cloud-based health information
platform, found in Resolve's debut product Breeze, address the numerous
issues with currently available methods of cannabis delivery –
establishing a standard of care and rigorous medical approach for the
medical cannabis industry. With over three years of research and
development, the complete product ecosystem will be initially available
in select dispensaries in early 2018. For more information, visit:

www.mybreeze.co

www.resolvedigitalhealth.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain
information in this news release constitutes forward-looking statements
under applicable securities laws. Any statements that are contained in
this news release that are not statements of historical fact may be
deemed to be forward-looking statements. Forward-looking statements are
often identified by terms such as "may", "should", "anticipate",
"expect", "believe", "plan", "intend", "subject to" or the negative of
these terms and similar expressions. Forward-looking statements in this
news release include, but are not limited to, expectations concerning
receipt of approval from the Florida Department of Health, Office of
Medical Marijuana Use. Forward-looking statements necessarily involve
known and unknown risks, including, without limitation, risks associated
with general economic conditions; adverse industry events; marketing
costs; loss of markets; future legislative and regulatory developments
involving medical marijuana; inability to access sufficient capital from
internal and external sources, and/or inability to access sufficient
capital on favourable terms; the medical marijuana industry in the
United States generally, income tax and regulatory matters; the ability
of Liberty to implement its business strategies; competition; crop
failure; currency and interest rate fluctuations and other risks.

Readers are cautioned that the foregoing list is not exhaustive. Readers
are further cautioned not to place undue reliance on forward-looking
statements as there can be no assurance that the plans, intentions or
expectations upon which they are placed will occur. Such information,
although considered reasonable by management at the time of preparation,
may prove to be incorrect and actual results may differ materially from
those anticipated. Forward-looking statements contained in this news
release are expressly qualified by this cautionary statement.

View Comments and Join the Discussion!
 

Partner Center